<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02027272</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0269</org_study_id>
    <nct_id>NCT02027272</nct_id>
  </id_info>
  <brief_title>Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):</brief_title>
  <acronym>PRESIDEX</acronym>
  <official_title>Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): A Randomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blinded, placebo-controlled trial to determine if IV dexamethasone more
      quickly than placebo assists resolution of Posterior Reversible Encephalopathy Syndrome
      (PRES) encountered in eclamptic patients. All patients regardless of assignment to placebo or
      steroid will receive standard therapy to include magnesium sulfate, blood pressure
      medications and diuretics. We hypothesize that the addition of dexamethasone to standard
      therapy will accelerate CNS recovery more quickly than standard management without
      dexamethasone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 eclamptic patients who do not require steroids for fetal lung maturation purposes will be
      randomized to placebo or steroid. This includes patients with eclampsia encountered
      antepartum prior to 23 weeks gestation, postpartum eclampsia, undelivered patients
      encountered after 33 weeks gestation who would not be candidates for fetal lung maturation
      steroids, or patients not eligible for repeat steroid administration in the 23-34 week
      gestational window. Planned enrollment in this pilot study is up to 30 patients with at least
      12 in each group.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty recruiting, only one participant in 18 months, rarity of event
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): Arandomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery</measure>
    <time_frame>36 months</time_frame>
    <description>To learn if giving IV dexamethasone to eclamptic women with PRES will accelerate normalization of CNS function.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Eclampsia</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 12 mg, 2 doses, 12 hours apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 2 doses, 12 hours apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Potent glucocorticoid or steroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Currently 34 weeks pregnant or within 6 weeks postpartum

          2. At least 18 years of age

          3. Singleton or twin gestation

          4. Patient or family sign informed consent

          5. Diagnosis of eclampsia

          6. Able to obtain MRI scanning within 24hours of hosp admit and/or seizure

        Exclusion Criteria:

          1. Neither pregnant nor within first 6 weeks postpartum

          2. Patient or family unable to sign informed consent

          3. Less than 18 years of age

          4. Triplet or higher order gestation

          5. Unable to obtain MRI scanning within 24 hours of hospital admission (

          6. Diagnosis of cerebral hemorrhage

          7. Patient in whom MRI is contraindicated
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medican Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2013</study_first_submitted>
  <study_first_submitted_qc>January 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2014</study_first_posted>
  <results_first_submitted>April 19, 2016</results_first_submitted>
  <results_first_submitted_qc>April 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2016</results_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>James Martin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Eclampsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Posterior Leukoencephalopathy Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone</title>
          <description>Dexamethasone 12 mg, 2 doses, 12 hours apart.
Dexamethasone: Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, 2 doses, 12 hours apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone</title>
          <description>Dexamethasone 12 mg, 2 doses, 12 hours apart.
Dexamethasone: Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, 2 doses, 12 hours apart</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): Arandomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery</title>
        <description>To learn if giving IV dexamethasone to eclamptic women with PRES will accelerate normalization of CNS function.</description>
        <time_frame>36 months</time_frame>
        <population>Logistic hurdles caused to stop the study after the first participant and not proceed further. No analysis was undertaken.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>Dexamethasone 12 mg, 2 doses, 12 hours apart.
Dexamethasone: Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 2 doses, 12 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): Arandomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery</title>
          <description>To learn if giving IV dexamethasone to eclamptic women with PRES will accelerate normalization of CNS function.</description>
          <population>Logistic hurdles caused to stop the study after the first participant and not proceed further. No analysis was undertaken.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>No AE.</time_frame>
      <desc>No AE</desc>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone</title>
          <description>Dexamethasone 12 mg, 2 doses, 12 hours apart.
Dexamethasone: Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, 2 doses, 12 hours apart</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James N. Martin, Jr.</name_or_title>
      <organization>University of Mississippi Medical Center</organization>
      <phone>601-984-5358</phone>
      <email>jnmartin@umc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

